Physician profile
David Tobias
NPI 1881862357
$2,282.08
in general payments reported to CMS, 2019-2025
29 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $13.34 · 2021: $298 · 2022: $1,220 · 2023: $750.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $750.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $750.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $209.12 | 2021-2023 | |
| Glaxosmithkline, LLC. | $198.15 | 2022-2023 | Shingrix, Trelegy Ellipta |
| Lilly USA, LLC | $188.80 | 2022-2023 | Mounjaro |
| Abbvie INC. | $178.23 | 2022-2023 | Ubrelvy |
| Amgen INC. | $129.83 | 2021-2023 | Repatha |
| Novo Nordisk INC | $119.31 | 2021-2023 | Wegovy, Ozempic, Rybelsus |
| Biohaven Pharmaceutical Holding Company LTD. | $118.73 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $116.17 | 2021-2023 | Trintellix |
| Abbott Laboratories | $109.70 | 2023 | Freestyle Libre 2 |
| Pfizer INC. | $108.54 | 2022-2023 | |
| Astrazeneca Pharmaceuticals LP | $106.45 | 2022 | |
| Janssen Pharmaceuticals, INC | $79.51 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $73.23 | 2021-2023 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $64.25 | 2022-2023 | |
| Otsuka America Pharmaceutical, INC. | $63.23 | 2022-2023 | Rexulti |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $63.05 | 2022-2023 | |
| Merck Sharp & Dohme LLC | $54.58 | 2021-2022 | |
| Dexcom, INC. | $53.41 | 2022-2023 | Dexcom G6 Transmitter |
| Sanofi Pasteur INC. | $46.97 | 2022-2023 | |
| Corium, LLC | $42.72 | 2022-2023 | Azstarys |
| Alexion Pharmaceuticals, INC. | $24.77 | 2022 | |
| Eisai INC. | $23.07 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $20.92 | 2021 | |
| Vbi Vaccine (Delaware) INC. | $19.24 | 2023 | Prehevbrio |
| Astellas Pharma US INC | $14.90 | 2022 | |
| Medtronic, INC. | $14.40 | 2021 | |
| Idorsia Pharmaceuticals US INC | $14.37 | 2022 | |
| Ermi LLC | $13.34 | 2019 | |
| Neos Therapeutics, LP | $13.09 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Tobias listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.